Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response. (20th January 2017)
- Record Type:
- Journal Article
- Title:
- Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response. (20th January 2017)
- Main Title:
- Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response
- Authors:
- Marangon, Miriam
Vianelli, Nicola
Palandri, Francesca
Mazzucconi, Maria Gabriella
Santoro, Cristina
Barcellini, Wilma
Fattizzo, Bruno
Volpetti, Stefano
Lucchini, Elisa
Polverelli, Nicola
Carpenedo, Monica
Isola, Miriam
Fanin, Renato
Zaja, Francesco - Abstract:
- Abstract: Objectives: To evaluate the efficacy of a salvage treatment with rituximab (RTX) in adults with primary immune thrombocytopenia (ITP), in terms of short‐term response and long‐term response (LTR, i.e., probability to achieve and maintain response) and to identify biological and clinical predictors of response. Methods: We retrospectively evaluated the outcome of patients with primary ITP treated with standard dosage RTX (375 mg/m 2 × 4) as salvage therapy in five Italian centers. One hundred and three patients, median age of 46 yr, were included. The median period of observation was 59 months. Results: Response (R) and complete response (CR) were documented in 57 (55%) and 37 (36%) patients, respectively. Patients younger than 40 yr had a higher probability to achieve CR ( P = 0.025). Younger women (age < 40 yr) had a significantly higher probability to achieve R and CR ( P = 0.039 and P = 0.009, respectively). The estimated LTR rate was 36% and 31% after 48 and 72 months, respectively; female sex ( P = 0.033) and younger age ( P = 0.021) were associated with better LTR. Younger women had the highest LTR rate ( P = 0.006). Response duration was associated with the obtainment of CR after RTX (CR vs. partial response, P = 0.002). Conclusions: The effect of RTX salvage treatment appears higher in younger women, with LTR rate possibly approaching that of splenectomy.
- Is Part Of:
- European journal of haematology. Volume 98:Number 4(2017:Apr.)
- Journal:
- European journal of haematology
- Issue:
- Volume 98:Number 4(2017:Apr.)
- Issue Display:
- Volume 98, Issue 4 (2017)
- Year:
- 2017
- Volume:
- 98
- Issue:
- 4
- Issue Sort Value:
- 2017-0098-0004-0000
- Page Start:
- 371
- Page End:
- 377
- Publication Date:
- 2017-01-20
- Subjects:
- rituximab -- hemostaseology and platelets -- thrombocytes
Hematology -- Periodicals
Blood -- Diseases -- Periodicals
Blood -- Periodicals
616.15005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-0609 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=ejh ↗
http://onlinelibrary.wiley.com/ ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1111/ejh.12839 ↗
- Languages:
- English
- ISSNs:
- 0902-4441
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.729700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 1141.xml